{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:08:41Z","timestamp":1794438521187,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"DOI":"10.1038\/s41591-023-02210-0","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T15:58:21Z","timestamp":1676044701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6644-2264","authenticated-orcid":false,"given":"Hatem","family":"Soliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0991-3338","authenticated-orcid":false,"given":"Deanna","family":"Hogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1030-5054","authenticated-orcid":false,"given":"Blaise","family":"Mooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1756-7279","authenticated-orcid":false,"given":"Marie C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Niell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Falcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixa","family":"Soyano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avan","family":"Armaghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Khakpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4245-8744","authenticated-orcid":false,"given":"Robert J.","family":"Weinfurtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hoover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kiluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Laronga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilin","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Khong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Czerniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"2210_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini, G., De Angelis, C., Licata, L. & Gianni, L. Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs. Nat. Rev. Clin. Oncol. 19, 91\u2013113 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2210_CR2","doi-asserted-by":"publisher","first-page":"e0128345","DOI":"10.1371\/journal.pone.0128345","volume":"10","author":"W Zhu","year":"2015","unstructured":"Zhu, W. et al. Age-related disparity in immediate prognosis of patients with triple-negative breast cancer: a population-based study from SEER cancer registries. PLoS ONE 10, e0128345 (2015).","journal-title":"PLoS ONE"},{"key":"2210_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10549-014-3197-y","volume":"148","author":"M Miyashita","year":"2014","unstructured":"Miyashita, M. et al. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res. Treat. 148, 525\u2013534 (2014).","journal-title":"Breast Cancer Res. Treat."},{"key":"2210_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nm0697-639","volume":"3","author":"C Heise","year":"1997","unstructured":"Heise, C. et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3, 639\u2013645 (1997).","journal-title":"Nat. Med."},{"key":"2210_CR5","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1158\/1078-0432.CCR-20-3105","volume":"27","author":"H Soliman","year":"2021","unstructured":"Soliman, H. et al. A phase I trial of talimogene laherparepvec in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer. Clin. Cancer Res. 27, 1012\u20131018 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2210_CR6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810\u2013821 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2210_CR7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid, P. et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N. Engl. J. Med. 386, 556\u2013567 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2210_CR8","doi-asserted-by":"publisher","first-page":"S868","DOI":"10.1016\/j.annonc.2021.08.1422","volume":"32","author":"A Ribas","year":"2021","unstructured":"Ribas, A. et al. MASTERKEY-265: a phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB-IVM1c melanoma (MEL). Ann. Oncol. 32, S868\u2013S869 (2021).","journal-title":"Ann. Oncol."},{"key":"2210_CR9","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1001\/jamaoncol.2021.3690","volume":"7","author":"WF Symmans","year":"2021","unstructured":"Symmans, W. F. et al. Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer: an analysis of data from the I-SPY2 randomized clinical trial. JAMA Oncol. 7, 1654\u20131663 (2021).","journal-title":"JAMA Oncol."},{"key":"2210_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau, C. et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 23, 149\u2013160 (2022).","journal-title":"Lancet Oncol."},{"key":"2210_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19933-0","volume":"11","author":"YH Park","year":"2020","unstructured":"Park, Y. H. et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat. Commun. 11, 6175 (2020).","journal-title":"Nat. Commun."},{"key":"2210_CR12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl, S. et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol. 30, 1279\u20131288 (2019).","journal-title":"Ann. Oncol."},{"key":"2210_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cell.2017.11.036","volume":"172","author":"M Gaya","year":"2018","unstructured":"Gaya, M. et al. Initiation of antiviral B cell immunity relies on innate signals from spatially positioned NKT cells. Cell 172, 517\u2013533 (2018).","journal-title":"Cell"},{"key":"2210_CR14","doi-asserted-by":"publisher","first-page":"e002096","DOI":"10.1136\/jitc-2020-002096","volume":"9","author":"S Gebremeskel","year":"2021","unstructured":"Gebremeskel, S. et al. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis. J. Immunother. Cancer 9, e002096 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2210_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nrd.2016.178","volume":"15","author":"HL Kaufman","year":"2016","unstructured":"Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: a new class of immunotherapy drugs. Nat. Rev. Drug Discov. 15, 660 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2210_CR16","doi-asserted-by":"publisher","first-page":"146016","DOI":"10.1016\/j.gene.2021.146016","volume":"809","author":"B Kaur","year":"2022","unstructured":"Kaur, B., Mukhlis, Y., Natesh, J., Penta, D. & Musthapa Meeran, S. Identification of hub genes associated with EMT-induced chemoresistance in breast cancer using integrated bioinformatics analysis. Gene 809, 146016 (2022).","journal-title":"Gene"},{"key":"2210_CR17","first-page":"2661","volume":"16","author":"Z Zhu","year":"2018","unstructured":"Zhu, Z. et al. Expression of AQP3 and AQP5 as a prognostic marker in triple-negative breast cancer. Oncol. Lett. 16, 2661\u20132667 (2018).","journal-title":"Oncol. Lett."},{"key":"2210_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259\u2013271 (2015).","journal-title":"Ann. Oncol."},{"key":"2210_CR19","doi-asserted-by":"publisher","first-page":"e0185056","DOI":"10.1371\/journal.pone.0185056","volume":"12","author":"B Bushnell","year":"2017","unstructured":"Bushnell, B., Rood, J. & Singer, E. BBMerge\u2014accurate paired shotgun read merging via overlap. PLoS ONE 12, e0185056 (2017).","journal-title":"PLoS ONE"},{"key":"2210_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"2210_CR21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2014a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"2210_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"2210_CR23","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2210_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).","journal-title":"Genome Biol."},{"key":"2210_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4137\/CIN.S9983","volume":"11","author":"X Chen","year":"2012","unstructured":"Chen, X. et al. TNBCtype: a subtyping tool for triple-negative breast cancer. Cancer Inform. 11, 147\u2013156 (2012).","journal-title":"Cancer Inform."}],"updated-by":[{"DOI":"10.1038\/s41591-023-02309-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02210-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02210-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02210-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T14:46:26Z","timestamp":1722869186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02210-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":25,"alternative-id":["2210"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02210-0","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41591-023-02309-4","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"30 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Funding for the trial was provided by Amgen. H.S. has received consulting fees from AstraZeneca, Novartis, Seattle Genetics, PUMA, Sanofi and Eisai; licensing fees for intellectual property from Celyad Oncology; and institutional research funding from Amgen. H.K. has sat on the scientific advisory board for Celcuity; holds equities in Agenus, TG Therapeutics, Vexart, Lipocine, Mustang Bio, MEI Pharma and Tiziana Life Sciences; and has received institutional research support from AstraZeneca. M.C.L. has received research funding from Elucent Medical. S.H. has sat on the advisory board of Devicor\/Mammotome. H.H. has received fees for advisory and speaker bureau activities from Lilly, Novartis and Immunomedics. B.C. has received advisory fees from Merit Oncology and has intellectual property rights with Immunorestoration. M.R. has received speaker fees from Roche. A.W., D.H., S.F., A.S., N.K., J.K., C.L., A.A., R.C., R.J.W., B.M. and A.C. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}